{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(1)"],"submitter":["Junqueira DR"],"funding":["Takeda Pharmaceuticals U.S.A."],"pubmed_abstract":["<h4>Background</h4>Dopamine antagonists are the main pharmacological options to treat gastroparesis. The aim of this study was to conduct a systematic literature review (SLR) to evaluate the profile of adverse events (AEs) of dopamine antagonists used in the treatment of children and adults with gastroparesis.<h4>Methods</h4>We searched EMBASE and MEDLINE up to March 25, 2021, for relevant clinical trials and observational studies. We conducted a proportional meta-analysis to estimate the pooled occurrence of AEs (%), with 95% confidence interval (CI), from arm-level data across studies and the comparative occurrence of AEs from placebo-controlled clinical trials (odds ratio [OR] with 95% CI).<h4>Results</h4>We identified 28 studies assessing AEs experienced by patients treated for gastrop"],"journal":["Drugs in R&D"],"pagination":["1-20"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9985532"],"repository":["biostudies-literature"],"pubmed_title":["Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis."],"pmcid":["PMC9985532"],"pubmed_authors":["Betts M","Junqueira DR","Bennett D","Huh SY","Fahrbach K","Neupane B"],"additional_accession":[]},"is_claimable":false,"name":"Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis.","description":"<h4>Background</h4>Dopamine antagonists are the main pharmacological options to treat gastroparesis. The aim of this study was to conduct a systematic literature review (SLR) to evaluate the profile of adverse events (AEs) of dopamine antagonists used in the treatment of children and adults with gastroparesis.<h4>Methods</h4>We searched EMBASE and MEDLINE up to March 25, 2021, for relevant clinical trials and observational studies. We conducted a proportional meta-analysis to estimate the pooled occurrence of AEs (%), with 95% confidence interval (CI), from arm-level data across studies and the comparative occurrence of AEs from placebo-controlled clinical trials (odds ratio [OR] with 95% CI).<h4>Results</h4>We identified 28 studies assessing AEs experienced by patients treated for gastrop","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-03-17T15:23:43.418Z","creation":"2025-02-18T23:35:26.017Z"},"accession":"S-EPMC9985532","cross_references":{"pubmed":["36749528"],"doi":["10.1007/s40268-023-00413-x"]}}